MAX and plasma cell myeloma: Our studies identified a novel dual-targeting c-Myc inhibitor D347-2761, which could block c-Myc/Max heterodimerization and disturb c-Myc protein stability to further repress multiple myeloma growth in vitro and in vivo via inhibiting CDK4 promoter transcriptional activity.